Good Results Stop Novartis’ Phase III Everolimus Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral mTOR inhibitor could beat Wyeth’s IV Torisel in kidney cancer, Novartis exec tells “The Pink Sheet” DAILY.
You may also be interested in...
Novartis’ RAD001 Doubles Progression-Free Survival in Advanced Renal Cancer Trial
Median PFS was 4 months with everolimus, versus 1.9 months with placebo.
Novartis’ RAD001 Doubles Progression-Free Survival in Advanced Renal Cancer Trial
Median PFS was 4 months with everolimus, versus 1.9 months with placebo.
ASCO Early Release Offers Highlights, But The Best Is Yet To Come
Part one of “The Pink Sheet” DAILY’s review of roughly 5,000 abstracts released ahead of the American Society of Clinical Oncology annual meeting.